DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on March 2, 2005; DOI: 10.1124/dmd.104.002592


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.002592v1
33/6/739    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonate, P. L
Right arrow Articles by Rose, J. Q
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonate, P. L
Right arrow Articles by Rose, J. Q


Received for publication October 5, 2004.
Revised February 15, 2005.
Accepted for publication February 23, 2005.

The Distribution, Metabolism, and Elimination of Clofarabine in Rats

Peter L Bonate 1*, Larry Arthaud 1, John Stuhler 2, Phyllis Yerino 2, Randall J Press 2, James Q Rose 2

1 Genzyme Oncology 2 Quintiles

* Address correspondence to: E-mail: peter.bonate{at}genzyme.com

Abstract

The distribution, metabolism and elimination of intravenous 14C-clofarabine was studied in Fischer 344 male rats under a once daily for 5 days dosing schedule of 25 or 50 mg/kg/day. Also, the in vitro metabolism in rat, dog, and human hepatocytes was studied. Plasma radioactivity (of which clofarabine accounted for 63% to 93%) exhibited three phases of exponential elimination with half-lives of 0.3, 1.3, and 12.8 hours after administration of the 25 mg/kg/d regimen. Unscheduled deaths occurred after 1 to 3 doses with the 50 mg/kg regimen, possibly due to nonlinear pharmacokinetics, and so mass balance and radiokinetic profiles could not be obtained. A total of 77.1% (of which 87.2% was clofarabine) and 10.8% (of which 6.9% was clofarabine) of the dose was recovered in urine and feces, respectively. 6-ketoclofarabine, believed to be formed via adenosine deaminase, was the metabolite of greatest concentration found in urine and feces, but in each matrix accounted for only 7% of the daily recovery of radioactivity. 6 ketoclofarabine was also found in myocardium and liver, but accounted for less than 2% of the total radioactivity in those tissues. Clofarabine was the major analyte found in myocardium (> 97% region of integration) and liver (> 94% region of integration). Whole body autoradiography demonstrated that the highest postdistributive concentrations of radioactivity were in the excretory organs, kidney, bladder and GI tract, with no remarkable suborgan distribution. In rat, dog, and human hepatocytes, 95, 96, and 99.8% [14C]-clofarabine remained, respectively, after 6 hours incubation. Eleven metabolites were observed with the largest constituting 2.5% of the radioactivity.


Key words: anticancer agents, hepatocytes, kinetic modeling, renal elimination


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
K. M. King, V. L. Damaraju, M. F. Vickers, S. Y. Yao, T. Lang, T. E. Tackaberry, D. A. Mowles, A. M. L. Ng, J. D. Young, and C. E. Cass
A Comparison of the Transportability, and Its Role in Cytotoxicity, of Clofarabine, Cladribine, and Fludarabine by Recombinant Human Nucleoside Transporters Produced in Three Model Expression Systems
Mol. Pharmacol., January 1, 2006; 69(1): 346 - 353.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.